Oral Solubilized Ursodeoxycholic Acid Therapy in Amyotrophic Lateral Sclerosis: A Randomized Cross-Over Trial.
10.3346/jkms.2012.27.2.200
- Author:
Ju Hong MIN
1
;
Yoon Ho HONG
;
Jung Joon SUNG
;
Sung Min KIM
;
Jung Bok LEE
;
Kwang Woo LEE
Author Information
1. Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- Publication Type:Original Article ; Clinical Trial, Phase III ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
- Keywords:
Amyotrophic Lateral Sclerosis;
Ursodeoxycholic Acid;
Cross-Over Trial
- MeSH:
Administration, Oral;
Amyotrophic Lateral Sclerosis/*drug therapy;
Cholagogues and Choleretics/pharmacology/therapeutic use;
Cross-Over Studies;
Double-Blind Method;
Female;
Humans;
Male;
Middle Aged;
Placebo Effect;
Severity of Illness Index;
Ursodeoxycholic Acid/pharmacology/*therapeutic use;
Vital Capacity/drug effects
- From:Journal of Korean Medical Science
2012;27(2):200-206
- CountryRepublic of Korea
- Language:English
-
Abstract:
To evaluate the efficacy and safety of ursodeoxycholic acid (UDCA) with oral solubilized formula in amyotrophic lateral sclerosis (ALS) patients, patients with probable or definite ALS were randomized to receive oral solubilized UDCA (3.5 g/140 mL/day) or placebo for 3 months after a run-in period of 1 month and switched to receive the other treatment for 3 months after a wash-out period of 1 month. The primary outcome was the rate of progression, assessed by the Appel ALS rating scale (AALSRS), and the secondary outcomes were the revised ALS functional rating scale (ALSFRS-R) and forced vital capacity (FVC). Fifty-three patients completed either the first or second period of study with only 16 of 63 enrolled patients given both treatments sequentially. The slope of AALSRS was 1.17 points/month lower while the patients were treated with UDCA than with placebo (95% CI for difference 0.08-2.26, P = 0.037), whereas the slopes of ALSFRS-R and FVC did not show significant differences between treatments. Gastrointestinal adverse events were more common with UDCA (P < 0.05). Oral solubilized UDCA seems to be tolerable in ALS patients, but we could not make firm conclusion regarding its efficacy, particularly due to the high attrition rate in this cross-over trial.
